Citrus Health Group

Citrus Health Group structures capital around clinical and regulatory milestones for life sciences companies — primarily biotechnology, specialty pharma, and select medical-device issuers. The approach uses royalty-based financing, pre-approval convertible notes, and direct equity positions, each sized to specific binary events such as Phase II/III data readouts and FDA decision dates. This is milestone finance rather than traditional venture capital, with timeline risk managed through structured deal terms rather than portfolio diversification alone.

The firm underwriting is directly tied to individual clinical-trial catalysts and regulatory-action calendars, not to long-duration platform-company building. Term sheets often reference specific data-readout dates, priority-review designations, and commercial-launch triggers, converting drug-development risk into a time-delimited financial instrument. By using royalty monetization and structured-debt tranches alongside equity, the firm captures milestone-based upside while adjusting downside exposure with repayment schedules keyed to approval outcomes.

The firm operates across both private and public life sciences companies — particularly public issuers with near-term regulatory catalysts where pre-approval financing can be structured around specific FDA decision dates. This crossover capability allows Citrus Health Group to allocate where clinical binary risk is highest and conventional equity-investor appetite is most constrained, including pre-PDUFA rescue-financing scenarios that generalist healthcare funds avoid.

The firm concentrates on oncology platform developers, rare-disease therapeutics, and select specialty pharmaceutical assets, with a discernible preference for programs carrying clearly defined FDA endpoints such as accelerated-approval pathways or breakthrough-therapy designations. It does not appear to target medical-device diagnostics or health-IT services, focusing instead on therapeutic products where a single pivotal trial or regulatory decision can serve as the primary valuation and exit trigger.

Philadelphia sits at the center of a dense life-sciences corridor extending through central New Jersey — home to a significant share of US cell-and-gene-therapy manufacturing capacity, academic-medical research infrastructure, and FDA-facing regulatory consultancies. The firm leverages this geography to access deal flow from regional biotech clusters and to build externalized drug-development expertise through relationships with contract research organizations and advisory networks, rather than staffing a full in-house clinical-operations team.